Agilent Technologies A · NYSE
$172.94 -1.49% (-$2.61)
Summary
65 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 20 USD is left as net profit.
- It has raised its dividend 10 years in a row and pays out only 20% of profit.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 0.5% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 34.4 USD for 1 USD of yearly profit. Over the last five years it was 31.8 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.4% a year over 5 years. Over the last 3 years it grew by 0.5% a year. For the next fiscal year analysts expect revenue to grow by 8.0%. Earnings per share grew by 3.0% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 35 USD
- Research and development 6.6 USD
- Sales and administration 25 USD
- Taxes and other 2.7 USD
- Net profit 20 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 20 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.58%
- Paid out of profit
- 20%
- Raised in a row
- 10 years
You receive $1.01 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 33
- Hold 7
- Sell 1
Today's price within the analysts' price targets
The average target of $170 is 1.7% below today's price. 80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Agilent CrossLab 42%
- Life Sciences and Applied Markets 39%
- Applied Markets 19%
By region
- Americas 40%
- Asia Pacific 32%
- Europe 28%
Agilent CrossLab brings in 42% of revenue.
Segments in detail